期刊
PHARMACOLOGY & THERAPEUTICS
卷 178, 期 -, 页码 132-140出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2017.04.002
关键词
Antimicrobial peptides (AMPs); Synthetic peptides; Antibiotic resistance; Immune modulation; Infectious diseases; Inflammation; Vitamin D; Host-directed therapy
资金
- Fundacao para a Ciencia e a Tecnologia - Ministerio da Ciencia, Tecnologia
- CNPq
- CAPES
- FADPDF
- FINEP
- FUNDECT
- Ramon Areces Foundation (Spain)
- National Council of Technological and Scientific Development (CNPq)
- Fundacao Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) [300583/2016-8]
- National Institutes of Health [1P50GM098792, 1R21AI12166901]
- National Science Foundation [MCB-1350625]
- Defense Threat Reduction Agency [HDTRA1-14-1-0007, HDTRA1-15-1-0050]
- Defense Advanced Research Projects Agency
- Office of Naval Research
- Army Research Office
- Center for Microbiome Informatics and Therapeutics
- Broad Institute of MIT and Harvard
- Koch Institute for Integrative Cancer Research
- Kuwait-MIT Center for Natural Resources and Environment
Antimicrobial peptides (AMPs) have evolved through billions of years as part of our innate immune system. These agents are produced by various cells throughout the human body and play important roles in our ability to respond to infections. In this review, we outline evidence linking AMP expression with a range of inflammatory and autoimmune human diseases. Finally, we highlight the promise of endogenous AMP induction for the treatment of disease (i.e., host-directed therapy) and briefly mention the different peptide drugs that are currently undergoing clinical trials. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
